



What is DAR?

Herein you will find Drug Assessment Reports for new drugs. They are elaborated by the Navarre Drug Assessment working group in collaboration with the rest of the Mixed Committee for New Drugs Assessment (MCNDA). The MCNDA was set up in 2003 and is made up of the individual committees from Andalusia, Basque Country, Catalonia Health Institute, Aragon and Navarre. Its main objectives are:

- to **evaluate** the degree of therapeutic innovation in the new drugs in comparison with what is already available on the market
- to provide specific **recommendations** to the health professionals about these drugs

The MCNDA has a Normalized Working Method which guarantees that the new drugs evaluation processes are carried out in a homogeneous way and with consensus among the different constituent committees. The degree of therapeutic innovation of each new drug is determined in accordance with criteria of efficiency, safety, treatment and cost. A classification is then assigned within a range of five categories by reaching a decision algorithm. Please find below the qualification categories for new drugs according to their innovation therapy:

Categories		Definition
0	Not possible to assess: Insufficient evidence	Available evidence is insufficient or inconclusive, or lacks good quality clinical trials including an adequate comparative drug.
1	No therapeutic innovation	The new drug has no added value over other drugs which are already available in the market for the same indication.
2	Some added value in specific situations	The new drug may have an added value in a particular condition or patient subgroup
3	Modest therapeutic innovation	The new drug provides more posology comfort or it lowers treatment cost
4	Important therapeutic innovation	The new drug provides added value in terms of efficacy or safety compared to the available therapeutic alternatives for the same indication or condition

For each drug there is an abbreviated version and a full text report as well. The latter is only available in Spanish. Sometimes a critical valuation on the advertising material of the Drug Companies related to new drugs is performed (available in Spanish only).